The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...

Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...

Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to ...

As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...

Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...

Amarillo Biosciences (OTCMKTS:AMAR) recently entered into a Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a corporation majority-owned by Mitsubishi Tanabe Pharma Corporation ...

Dewpoint Therapeutics CEO Ameet Nathwani stated: “This partnership underscores the transformative potential of our small ...

JERSEY CITY, N.J., Dec. 4, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of two abstracts on investigational ND0612 in Parkinson's disease (PD ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 10 presentations covering advances in amyotrophic lateral sclerosis (ALS) research at the Motor Neurone Disease Association (MNDA) 35th ...

Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, ...

Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of 97% of ALS patients - Mitsubishi Tanabe ...

with the potential to address the underlying pathology of <97% of ALS patients - Mitsubishi Tanabe Pharma Corporation obtains an option for a global license to develop and commercialize the novel ...